Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

66.7%

-19.9% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 1
4(57.1%)
Phase 2
3(42.9%)
7Total
Phase 1(4)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials
NCT03862430Phase 2Active Not Recruiting

A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM

Role: lead

NCT07748299Unknown

NuvOx Expanded Access

Role: lead

NCT07417774Enrolling By Invitation

Liquid Biopsy in Glioblastoma Treated With Chemoradiation and an Oxygen Therapeutic

Role: lead

NCT06658535Phase 1Recruiting

A Dose Escalation Study of NanO2 in Patients With Mild Respiratory Distress

Role: lead

NCT06821347Phase 2Not Yet Recruiting

NanO2 in Large VessEL Occlusion Stroke (NOVEL)

Role: collaborator

NCT05389748Phase 2Unknown

NanO2 for Large Vessel Occlusion Stroke

Role: lead

NCT02963376Phase 1Completed

A Phase Ib/II in Patients With Acute Ischemic Stroke

Role: lead

NCT02189109Phase 1Completed

The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma

Role: lead

NCT03013426Phase 1Withdrawn

A Phase Ib Study of NVX-508 in Sickle Cell Disease

Role: collaborator

All 9 trials loaded